Citadel Advisors’s ProShares Ultra CRCL CRCA Stock Holding History

Citadel Advisors’s Portfolio CRCA Stock Details CRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$804K	Buy	19,480 +13,180	+209%	+$547K	﹤0.01%	8171
2025 Q4	$255K	Buy	6,300 +2,820	+81%	+$242K	﹤0.01%	10510
2025 Q3	$509K	Buy	+3,480	New	+$560K	﹤0.01%	9089

Other funds holding CRCA

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citadel Advisors's CRCA Position: Q1 2026 in Review

Citadel Advisors increased its ProShares Ultra CRCL (CRCA) stake by 210% in Q1 2026, buying an estimated $1.32M and bringing the position to 47,007 shares worth $1.94M. The position accounts for ﹤0.01% of the portfolio, ranked #6120.

Citadel Advisors first reported a position in CRCA in Q4 2025 and has held it in 2 quarters since. 7 funds tracked by Wall St. Rank hold CRCA as of Q1 2026.

Citadel Advisors held 47,007 shares of ProShares Ultra CRCL worth $1.94M as of Q1 2026.
Citadel Advisors bought 31,859 ProShares Ultra CRCL shares in Q1 2026, an estimated $1.32M.
ProShares Ultra CRCL made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6120 holding.
Citadel Advisors first reported a position in ProShares Ultra CRCL in Q4 2025 and has held it in 2 quarters since.
7 funds tracked by Wall St. Rank held ProShares Ultra CRCL as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.